[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reported a routine withholding of 403 shares of Common Stock on 08/14/2025 to satisfy mandatory tax withholding when restricted stock units vested. The withheld shares were disposed at a reported price of $1.39 per share. After the transaction, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to cover taxes tied to RSU vesting.

Insights

Securities Analyst

TL;DR: A routine RSU tax-withholding disposed of a small number of shares; no material change to ownership position.

The reported transaction appears administrative: 403 shares were withheld at $1.39 to satisfy tax obligations upon RSU vesting, leaving 15,686 shares beneficially owned. Such withholdings are common and typically neutral for investors because they do not reflect a voluntary sale for liquidity or a change in insider conviction.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 reporting; transaction is procedural and non-material.

The Form 4 clearly identifies the reporting person, relationship to the issuer, transaction date, code F(1) indicating shares withheld for tax withholding, and resulting ownership. Documentation includes a power of attorney signature. There are no indications of unexpected executive departures, unusual timing, or material governance concerns in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gamelin Erick

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		F(1)		403	D	$1.39	15,686	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Adam D. Levy, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did ACRV insider Erick Gamelin report on Form 4?

The filing reports the withholding of 403 shares on 08/14/2025 to satisfy tax withholding on vested RSUs, at a price of $1.39 per share.

How many ACRV shares does Erick Gamelin beneficially own after the transaction?

After the withholding, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock.

What does transaction code F(1) mean on this Form 4 for ACRV?

Code F(1) is used here to indicate shares were withheld by the issuer to satisfy mandatory tax withholding upon vesting of restricted stock units.

When was the Form 4 for Erick Gamelin signed and filed?

The filing shows the transaction date as 08/14/2025 and bears a signature by an attorney-in-fact dated 08/18/2025.

Does this Form 4 indicate a voluntary sale of ACRV shares by the insider?

No. The reported disposition was a withholding by the issuer for tax purposes related to RSU vesting, not a voluntary open-market sale, per the filing.